Introduction {#s01}
============

Skin and mucosal epithelia of digestive, genitourinary, respiratory, and ocular systems comprise the largest surface area of the body. They are in direct contact with the external environment and therefore exposed to microorganisms that are potentially pathogenic, including bacteria, fungi, parasites, and viruses. These surfaces produce and deploy an array of antimicrobial molecules as one of their first lines of defense. Antimicrobial peptides (AMPs) belong to diverse families of oligopeptides (*\~*10--50 amino acid residues) that are evolutionarily conserved and widespread across all kingdoms of life ([@bib86]; [@bib91]). The general mechanism of action of AMPs includes killing of the pathogens by membrane disruption or inactivation of their life cycle and growth ([@bib85]). In addition, many AMPs function in the host as potent regulators of innate and adaptive immune responses and as agonists of angiogenesis and wound healing ([@bib37]; [@bib43]). Collectively, these processes effectively control microbial infections and maintain tissue health and homeostasis.

Keratin is the most abundant class of intermediate filament protein in the skin and mucosal epithelium ([@bib89]). Humans have \>50 keratins, which are classified as either acidic type I keratins (K9--K10, K12--K28, and K31--K40) or as basic type II keratins (K1--K8 and K71--K86; [@bib50]). Both types are expressed in keratinocytes and epithelial cells and are characterized by a central conserved α-helical rod domain containing coiled-coil motifs for dimerization and spanned by divergent short non--α-helical head and tail domains for protein--protein interactions ([@bib18]). Type I and type II keratins form cytosolic heterodimers and oligomers at cell focal adhesion sites ([@bib88]). These subunits are incorporated into filamentous keratin networks at the cell periphery, which in turn coalesce into fibrous bundles at the perinuclear space, providing mechanical support and protection to the cell ([@bib28]; [@bib89]). Conversely, the disassembly of the filamentous keratin network to yield soluble subunits reusable for the next round of assembly is equally important, as this allows the filamentous keratin network to adapt to changing functional needs of the cell ([@bib28]; [@bib89]; [@bib56]).

Dynamic assembly and disassembly of the keratin network are driven by posttranslational modifications (PTMs) including site-specific phosphorylation ([@bib73]; [@bib70]). In general, phosphorylation at serine and threonine residues promotes disassembly of the keratin filamentous network. Keratin members are often modified by PTMs to regulate nonmechanical functional effects as well ([@bib73]; [@bib70]). For example, K8 can be heavily phosphorylated to absorb excess ATP that would otherwise be used by other pathways to activate proapoptotic factors leading to uncontrolled liver damage ([@bib31]; [@bib34]). Hyperphosphorylation of K8 and its heterotypic partner K18 are biomarkers for chronic hepatitis C virus infection of the liver ([@bib80]). Individuals who carry a rare K8 G61C mutation are prone to develop liver diseases such as hepatic cirrhosis ([@bib32]). This mutation sterically obstructs K8 phosphorylation at S73 by stress-activated kinases, reducing its solubility and availability as a phosphate sponge during hepatotoxic assault ([@bib31]; [@bib34]). This phenotype has been confirmed in transgenic mice models harboring either the human K8 G61C or S73A mutation ([@bib31]). Aberrant expression and phosphorylation of these and other type I or type II keratin members also occur during acute viral infection, although the pathological consequence is unclear ([@bib62]; [@bib53]; [@bib47]).

We previously reported a series of naturally occurred and overlapping short peptides (13--26 amino acids) from the carboxyl terminal region (residues 515--559) of keratin 6a (K6a), termed keratin-derived AMPs (KAMPs; [@bib78]; [@bib38]). KAMPs are constitutively expressed in human corneal epithelial cells and display potent antibacterial and cytoprotective effects against multiple bacterial pathogens. Whereas canonical AMPs such as defensins and cathelicidin are salt sensitive and disrupt bacterial membrane through electrostatic interaction and defined secondary structure determinants (α-helix and/or β-sheet; [@bib85]), KAMPs are salt tolerant and mediate membrane disruption through a distinct and different mechanism involving flexible glycine-rich sequences ([@bib78]). KAMPs are the only human example of a structurally unique class of non-αβ AMPs ([@bib69]; [@bib38]), which represent a new class of antimicrobial agents that can potentially address the public health requirement to tackle antibiotic-resistant bacteria ([@bib11]; [@bib43]).

Although K6a is constitutively expressed in many stratified epithelial tissues, including the cornea ([@bib50]; [@bib9]), and is induced by inflammatory cytokines during tissue injury and repair ([@bib29]; [@bib66]), the regulation of filamentous K6a remodeling and the mechanism of K6a processing into KAMPs remain elusive. In this study, we demonstrate the roles of PTMs and the ubiquitin--proteasome system (UPS) in these processes in the context of corneal innate immune defense. The K6a filament network depolymerizes in response to bacterial cell wall products and flagellin. Although K6a gene expression is not up-regulated under these conditions, cytosolic K6a and KAMP levels are significantly increased, suggesting that the filamentous form of K6a acts as a reserve pool of KAMP precursors. Furthermore, we report that S19, S22, S37, and S60 are the phosphorylation sites on K6a that enhance its solubility and that cytosolic K6a is targeted for ubiquitination by cullin--RING E3 ligases (CRLs) followed by proteasomal processing to produce KAMPs. These data provide novel mechanistic insights into the antimicrobial roles of cytokeratins and UPS in epithelial innate defense.

Results {#s02}
=======

Bacterial ligands trigger filamentous K6a network reorganization {#s03}
----------------------------------------------------------------

We first tested the hypothesis that the filamentous keratin network in epithelial cells undergoes reorganization in response to bacterial products. We used a telomerase-immortalized human corneal epithelial cell line (hTCEpi) that undergoes differentiation, stratification, and desquamation similar to the native corneal epithelium ([@bib63], [@bib64], [@bib65]). It is well established that human corneal epithelial cells express functional Toll-like receptors (TLRs) that recognize distinct pathogen-associated molecular patterns ([@bib92]; [@bib25], [@bib26]; [@bib82]; [@bib36]; [@bib67]); thus, we treated hTCEpi cells with purified bacterial surface structures from gram-positive and gram-negative bacteria, namely flagellin, lipopolysaccharide (LPS), or lipoteichoic acid (LTA), which activate TLR-5, TLR-4 and TLR-2, respectively, and compared the filamentous K6a organization in these cells by immunocytochemistry. To induce expression of the TLR-4 coreceptor MD-2 and thereby enable LPS/MD-2/TLR-4 signaling, these cells were pretreated briefly (2 h) with IFN-γ ([@bib67], [@bib68]). Using confocal microscopy, we observed that the filamentous K6a network in hTCEpi cells became more diffused in response to bacterial ligands compared with untreated control cells and that the reduction of filament density at the perinuclear region was particularly evident ([Fig. 1 A](#fig1){ref-type="fig"}). Similar observations were made for telomerase-immortalized human mammary epithelial cells and, to some extent, for SV40-immortalized human ectocervical epithelial cells (Fig. S1). In contrast, the K6a network in hTCEpi cells not primed with IFN-γ (deficient in MD-2) did not respond to LPS and showed no appreciable difference from untreated control cells (Fig. S2). We further quantified the fluorescence signal intensity of these filaments in hTCEpi cells along the distance from the nucleus to the plasma membrane and confirmed our observation ([Fig. 1 B](#fig1){ref-type="fig"}). As keratin filaments are known to disassemble and release reusable subunits at the perinuclear region ([@bib89]), the reduced filament density in bacteria ligand--treated hTCEpi cells suggests disassembly of K6a cytoskeleton as an epithelial response to bacterial pathogens.

![**Bacterial ligands trigger depolymerization of the filamentous K6a network. (A)** Confocal microscopic images of hTCEpi cells treated with vehicle, flagellin (FliC; 0.5 µg/ml), LPS (1 µg/ml), or LTA (1 µg/ml) for 16 h followed by immunostaining for K6a (green) and counterstaining for nuclei (red). For cells treated with LPS, a 2-h pretreatment with IFN-γ (250 ng/ml) was used to induce LPS responsiveness. The intense filamentous K6a network staining surrounding the nucleus in the control cell (insets) became diffused and weak after stimulation with bacterial ligands. Bars, 10 µm. **(B)** Quantification of fluorescence signal intensity of K6a filament as a function of the distance (μm) from the nucleus toward the plasma membrane using ImageJ. Signal intensity of each cell was measured along three lines at 0.06 µm steps to obtain a mean. The intensity values were normalized to the nuclear signal. Means ± SEM of 11--14 cells pooled from three to four independent experiments are shown. K6a filament intensity of treated cells was reduced significantly compared with control (P \< 0.0001).](JCB_201704186_Fig1){#fig1}

Bacterial ligands promote solubility of K6a and production of its antimicrobial fragments (KAMPs) {#s04}
-------------------------------------------------------------------------------------------------

In an effort to understand the significance of K6a network reorganization, we assessed the levels of cytosolic K6a and its antimicrobial fragments (KAMPs) in hTCEpi organotypic culture treated with bacterial ligands. Immunoblotting of NP-40--soluble proteins in the cell lysates showed that flagellin, LPS (with IFN-γ preincubation), or LTA stimulation led to a significant increase in the level of cytosolic K6a protein without detectable changes in its filament level ([Fig. 2, A--C](#fig2){ref-type="fig"}). In conjunction, the level of KAMPs in the same samples showed marked increase after stimulation ([Fig. 2, A--C](#fig2){ref-type="fig"}). To determine whether K6a gene expression was affected by exposure to these bacterial ligands, we used real-time PCR to quantify K6a mRNA and found no significant differences between control and stimulated cells ([Fig. 2 D](#fig2){ref-type="fig"}), thereby eliminating the possibility that the increased availability of cytosolic K6a is caused by elevated gene expression. Collectively, these data suggest that a slight shift of K6a from the filamentous to cytosolic form is sufficient to up-regulate KAMPs production without negatively impacting the mechanical properties of the cells.

![**Bacterial ligands promote K6a solubility and production of KAMPs. (A--C)** Immunoblot analysis of NP-40--soluble and -insoluble lysate fractions of hTCEpi organotypic culture treated with vehicle control or flagellin (FliC; 0.5 µg/ml; A), LPS (1 µg/ml; B), or LTA (1 µg/ml; C) for 16 h. For cells treated with LPS, a 2-h pretreatment with IFN-γ (250 ng/ml) was used to induce LPS responsiveness. Cytosolic K6a (60 kD) in the NP-40--soluble lysate fractions (10 µg total protein) and filamentous K6a (60 kD) in the insoluble fractions (1 µg total protein) were resolved in 12% Bis-Tris gels followed by immunoblotting. Same soluble lysate fractions (40 µg total protein) were also resolved in 16% tricine gel and immunoblotted for KAMPs (∼3 kD). Actin (42 kD) was used as a loading control. Quantification of band intensity was performed with Bio-Rad Laboratories Image Lab software and normalized with actin. Means ± SEM are shown. *n* = 4--8 independent experiments. \*\*, P \< 0.01; \*\*\*, P \< 0.001. **(D)** Quantitative RT-PCR assessment of K6a gene expression in hTCEpi cells treated with vehicle control, flagellin (FliC; 0.5 µg/ml), LPS (1 µg/ml), or LTA (1 µg/ml) for 3 and 6 h. K6a gene expression was normalized to actin. Compared with control cells, K6a gene expression in treated cells was unaffected under the indicated conditions (P \> 0.05). Means ± SD are shown. Experiments were performed three times.](JCB_201704186_Fig2){#fig2}

Serine phosphorylation of K6a augments its solubility in response to bacterial ligands {#s05}
--------------------------------------------------------------------------------------

As PTMs of intermediate filaments regulate their organization, assembly and disassembly dynamics, and, importantly, their functions ([@bib73]; [@bib70]), we investigated whether K6a is posttranslationally modified in response to bacterial ligands. Immunoprecipitation of K6a from the cytosolic extracts of hTCEpi organotypic culture in tandem with mass spectrometric analysis revealed four major phosphorylation sites of K6a at S19, S22, S37, and S60 ([Figs. 3 A](#fig3){ref-type="fig"}, S3, and S4). Either flagellin ([Fig. 3 B](#fig3){ref-type="fig"}) or LTA ([Fig. 3 D](#fig3){ref-type="fig"}) induced K6a double phosphorylation at S19 and S22 (∼4-fold and ∼1.5-fold of the basal level, respectively), whereas LTA also caused a modest increase of S60 phosphorylation (∼1.25-fold). In contrast, as shown in [Fig. 3 C](#fig3){ref-type="fig"}, LPS induced S37 phosphorylation (∼1.5-fold). Overall, the data demonstrate that bacterial ligands induce changes in serine phosphorylation of K6a.

![**Serine phosphorylation increases K6a solubility. (A)** Cytosolic K6a was immunoprecipitated from hTCEpi organotypic culture treated with various bacterial ligands followed by LC-MS analysis. Four different phosphopeptides were identified. **(B--D)** The degree of modification (abundance of phosphoform/abundance of unmodified form) was determined for each phosphopeptide. The fold amount of each modification after treatment relative to unstimulated control (basal levels = 1) is presented. **(E)** Phosphorylation of K6a positively correlates with its cytosolic level in hTCEpi organotypic culture. hTCEpi cells were treated with DMSO or 200 nM phosphatase inhibitor calyculin A for 5 h before they were harvested and immunoprecipitated (IP) with preimmune serum or anti-K6a antiserum. Samples were immunoblotted (IB) by anti-K6a antiserum or antiphosphoserine antibody. **(F)** Dephosphorylation of K6a by CIP. Remaining eluates from calyculin A--treated samples from E were divided into three fractions, resolved, transferred to polyvinylidene difluoride membrane, and incubated with CIP (fraction 3), without CIP (fraction 2), or CIP buffer only (fraction 1). Membranes were immunoblotted for K6a (fraction 1) or phosphorylated K6a (fractions 2 and 3).](JCB_201704186_Fig3){#fig3}

To substantiate the importance of serine phosphorylation of K6a, we treated hTCEpi organotypic culture with the phosphatase inhibitor calyculin A to inhibit the activity of protein phosphatase 1 and 2A and thereby induce hyperphosphorylation ([@bib76]). Immunoblotting using antiserum against K6a showed that the level of cytosolic K6a was drastically elevated in the presence of calyculin A ([Fig. 3 E](#fig3){ref-type="fig"}). As the level of filamentous K6a was concomitantly reduced, calyculin A caused a significant shift of K6a from the filamentous form to the cytosolic form. Furthermore, immunoprecipitation of cytosolic K6a followed by immunoblotting with an antibody against phosphoserine proteins indicated that a significant portion of cytosolic K6a was serine phosphorylated, which was confirmed by calf intestine phosphatase digestion ([Fig. 3, E and F](#fig3){ref-type="fig"}). These results demonstrate that phosphorylation of K6a at serine residues regulates its solubility.

Phosphorylation at ser-19, -22, -37, and -60 increases K6a solubility {#s06}
---------------------------------------------------------------------

Next, hTCEpi cells were transfected with plasmid constructs expressing HA-tagged WT K6a or K6a mutants with alanine substitutions at each of the four serine residues 19, 22, 37, and 60 that were identified by our mass spectrometric analysis as differentially phosphorylated in response to bacterial ligands ([Fig. 4 A](#fig4){ref-type="fig"}). Immunoblot analysis of the cytosolic fractions of these cells with an antibody against the HA tag showed that solubility of K6a with quadruple serine mutations (S19A/S22A/S37A/S60A) was substantially lower compared with the WT form ([Fig. 4 B](#fig4){ref-type="fig"}), supporting that phosphorylation at these serine sites mediates bacterial ligand-induced solubilization of K6a and in turn, KAMP production. Moreover, compared with the quadruple mutant, the solubility of the K6a triple mutant (S19A/S22A/S37A) was slightly improved, and the solubility of the double mutant (S19A/S22A) was improved further but remained lower than the WT ([Fig. 4 B](#fig4){ref-type="fig"}), suggesting that phosphorylation at S60 is insufficient and requires phosphorylation at the other three sites for optimal solubility. Likewise, as shown in [Fig. 4 C](#fig4){ref-type="fig"}, single mutations at S19, S22, S37, or S60 reduced the levels of cytosolic K6a to different extents, although the S37A mutation exhibited the strongest effect. Collectively, these data indicate that phosphorylation of any of these four serine residues promotes K6a solubility, whereas phosphorylation of all four serines maximizes solubility.

![**Site-specific serine-to-alanine K6a mutants are less soluble. (A)** hTCEpi cells were nucleofected with empty plasmid or plasmids encoding HA-tagged WT K6a or HA-tagged K6a mutants with various Ser-to-Ala mutations. After harvest, cells were disrupted by NP-40 lysis buffer to dissolve soluble K6a or by RIPA buffer supplemented with 8 M urea to dissolve both soluble and filamentous K6a into total K6a. **(B)** Solubilities of K6a mutants with multiple serine-to-alanine mutations. Note that the solubilities of the quadruple (S19A, S22A, S37A, and S60A) and triple mutants (S19A, S22A, and S37A) were drastically reduced compared with WT, whereas the double mutant (S19A and S22A) had noticeable improvement. **(C)** Solubilities of K6a single serine-to-alanine mutants. Note that the single S19A, S22A and S37A mutants displayed markedly reduced solubilities compared with WT, with the S37A mutant being the least soluble. In contrast, the solubility of the S60A mutant was comparable to WT. Experiments were performed three times. IB, immunoblot.](JCB_201704186_Fig4){#fig4}

The UPS degrades cytosolic K6a to generate KAMPs {#s07}
------------------------------------------------

The UPS is reported to degrade excess K8/K18 subunits released from the intermediate filament network in simple epithelial cells in response to shear stress and as a normal protein turnover mechanism ([@bib30]; [@bib22]). These observations prompted us to investigate whether K6a in the cytosolic pool is processed by the UPS to produce KAMPs. We treated hTCEpi organotypic culture with 200 nM of the proteasome inhibitor epoxomicin, which is a potent and specific inhibitor of all three peptidase activities of both constitutive and immune proteasomes ([@bib48]). We found that epoxomicin inhibited 80% of proteasomal trypsin-like peptidase activity without compromising cell viability ([Fig. 5 A](#fig5){ref-type="fig"}). We also found that under basal conditions and LTA stimulation, total ubiquitinated proteins in the cytosol were markedly increased as a result of proteasome inactivation ([Fig. 5 B](#fig5){ref-type="fig"}). Accumulation of ubiquitinated K6a was confirmed by blotting K6a immunoprecipitates with antiubiquitin antibody ([Fig. 5 B](#fig5){ref-type="fig"}). The immunoprecipitates were further analyzed by mass spectrometry. We detected that K6a was ubiquitinated at K180, K194, and K204 ([Figs. 5 C](#fig5){ref-type="fig"} and S5) and that damage-specific DNA binding protein 1 (DDB1), a substrate adapter protein for cullin 4 (CUL4; [@bib19]) of the CRL complexes, was coimmunoprecipitated with K6a. To determine whether CRLs are involved in K6a ubiquitination, we treated hTCEpi cells with 200 nM of MLN4924, which blocks cullin neddylation and thereby activation. It was evident that, especially after proteasome inhibition by epoxomicin, MLN4924 treatment reduced the levels of ubiquitinated K6a ([Fig. 5 D](#fig5){ref-type="fig"}), suggesting that K6a ubiquitination and subsequent processing by the proteasome is mediated in part by CRL family.

![**The UPS degrades soluble K6a to generate KAMPs. (A)** Effects of proteasome inhibition to the cell viability of hTCEpi organotypic culture. Cells pretreated with 0, 50, 100, or 200 nM of epoxomicin for 2 h followed by cotreatment with the same dosage of epoxomicin and LTA (1 µg/ml) for 16 h were incubated with MTT substrate solution or proteasome-Glo cell-based reagent. Cell viability across all epoxomicin concentrations was maintained ∼80--100% in contrast with a dose-dependent decrease in proteasome activities to as low as 20% at the highest concentration of epoxomicin used. Means ± SD (*n* = 4) are shown. **(B)** Effect of proteasome inhibition on the level of polyubiquitinated K6a. hTCEpi organotypic culture were treated with DMSO (lanes 1, 3, and 5) or epoxomicin (200 nM; lanes 2, 4, and 6) for 2 h followed by continual treatment with DMSO (vehicle control) or epoxomicin in the absence (lanes 1, 2, and 5) or presence (lanes 3, 4, and 6) of LTA (1 µg/ml) for 18 h. Cells were harvested and disrupted by RIPA lysis buffer, and lysates were immunoprecipitated (IP) with anti-K6a antiserum (lanes 1--4) or preimmune serum (lanes 5 and 6). Ubiquitinated K6a and total K6a were immunoblotted (IB) with antiubiquitin antibody (topmost panel) and anti-K6a antiserum (second panel) respectively. Epoxomicin promotes the accumulation of polyubiquitinated K6a (lanes 2 and 4). **(C)** Cytosolic K6a was immunoprecipitated from hTCEpi organotypic culture treated with various bacterial ligands in the presence or absence of epoxomicin. LC-MS analysis identified three different ubiquitination sites on K6a. **(D)** Effect of CRL inhibitor MLN4924 on the level of polyubiquitinated K6a. hTCEpi cells were pretreated with MLN4924 (200 nM) for 1 h followed by DMSO (lanes 1--3) or epoxomicin (lanes 4--6) treatment for 18 h. Cell lysates were immunoprecipitated with preimmune serum (lanes 1 and 4) or anti-K6a antiserum (lanes 2 and 3 and lanes 5 and 6). Note the decrease of polyubiquitinated K6a level when CRL was inhibited. **(E)** Effect of proteasome inhibition on the level of KAMPs. hTCEpi cells were treated with DMSO (lane 1) or epoxomicin (200 nM; lane 2) for 2 h followed by continual treatment with DMSO and epoxomicin in the presence of LTA (1 µg/ml) for 16 h before cell harvest and disruption by NP-40 lysis buffer to collect cytosolic fractions. The level of KAMPs decreased in the presence of epoxomicin. **(F)** Trypsin-like proteasome activity of hTCEpi cells was unaffected by bacterial ligand challenge (means ± SD). Experiments were performed at least three times. RLU, relative light unit.](JCB_201704186_Fig5){#fig5}

We next sought to assess the effect of proteasome inactivation on the level of cytosolic KAMPs in hTCEpi organotypic culture and found that the level of KAMPs was reduced in LTA-stimulated cells that were cotreated with epoxomicin ([Fig. 5 E](#fig5){ref-type="fig"}). To assess the physiological impact of proteasome inactivation and reduced KAMP production, we first tested the bactericidal activity of the \<10-kD cytosolic lysate fractions against *Pseudomonas aeruginosa*, which is an important cause of corneal infections and blindness. As shown in [Fig. 6 A](#fig6){ref-type="fig"}, the viable bacterial count after 3 h incubation was significantly higher in the lysate fraction from epoxomicin-treated hTCEpi organotypic culture compared with the untreated cell lysate fraction, indicating that proteasome activity is critical for endogenous antimicrobial activity. Furthermore, local administration of epoxomicin to the corneas of live mice drastically increased bacterial adherence to the intact corneal surface ex vivo ([Fig. 6 B](#fig6){ref-type="fig"}) and reduced bacterial clearance from the ocular surface in vivo ([Fig. 6 C](#fig6){ref-type="fig"}). These results are in agreement with our previous observation that knocking down K6a markedly reduced the bactericidal activity of hTCEpi cell lysates in vitro and increased bacterial adherence on murine corneas ex vivo ([@bib78]). Collectively, these data indicate that the UPS processes cytosolic K6a and generates KAMPs. Furthermore, although bacterial ligands triggered disassembly of the K6a filament network, leading to an increased cytosolic pool of K6a and KAMPs in hTCEpi cells ([Figs. 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), ligand stimulation did not affect the level of proteasomal trypsin-like activity in these cells ([Fig. 5 F](#fig5){ref-type="fig"}). These observations indicate that the availability of cytosolic K6a (substrate) is the major determinant for rapid and timely production of KAMPs (product) that is required particularly during the early stages of infection to efficiently eliminate pathogenic microbes.

![**The physiological impact of proteasome inactivation on corneal defense against *P. aeruginosa*. (A)** In vitro antibacterial activity. Organotypic culture of hTCEpi cells was stimulated with LTA for 16 h in the presence or absence of epoxomicin (200 nM). Cells were lysed and processed to obtain the \<10-kD lysate fractions. *P. aeruginosa* was added to the lysate fractions and incubated for 3 h at 37°C. Viable bacteria counts were determined after incubation. **(B)** Ex vivo antibacterial activity. Epoxomicin (80 pmol) or vehicle control was subconjunctivally delivered and topically administered to intact mouse cornea in vivo followed by exposure to bacterial culture supernatant. Enucleated eye balls were submerged in *P. aeruginosa* inoculum (10^11^ CFU/ml) for 3 h at 35°C. After extensive rinsing with PBS, corneas were dissected and homogenized to quantify bacterial adherence. **(C)** In vivo bacterial clearance activity. Mice were treated with epoxomicin and bacterial culture supernatant as described in B. *P. aeruginosa* (10^7^ CFUs total) was inoculated to mouse eyes in vivo. After 3 h, viable bacteria counts in the ocular surface washes were determined. Means ± SD are shown. \*\*, P \< 0.01; \*\*\*, P \< 0.001. Experiments were performed three times.](JCB_201704186_Fig6){#fig6}

Discussion {#s08}
==========

In this study, we demonstrate that PTM and the UPS regulate filamentous K6a network remodeling and AMP production in response to bacterial ligands in human corneal epithelial cells. Our data show that host cells respond to both gram-positive (i.e., LTA) and gram-negative (i.e., LPS and flagellin) bacterial ligands by depolymerizing the keratin cytoskeleton, which in turn increases the availability of soluble K6a and KAMPs in the cytosol. Using high-resolution mass spectrometry, we identified four serine residues (S19, S22, S37, and S60) in the K6a head domain that are phosphorylated under basal conditions. Importantly, phosphorylation of these sites is increased after stimulation with bacterial ligands and correlates with increased levels of cytosolic K6a. Mutating a single site or a combination of these sites from serine to alanine blocked this activity and reduced K6a solubility. Furthermore, cytosolic K6a is a ubiquitination substrate, which is targeted by the proteasome machinery for processing into KAMPs. The de novo synthesized KAMPs can then kill bacterial pathogens by disrupting their cell envelope via the flexible glycine-rich motif as we described previously ([@bib78]; [@bib38]). A major role of the proteasome is to generate antigenic peptides for MHC I presentation ([@bib46]); however, our findings reveal an essential role for the proteasome in production of KAMPs, which are an effective antimicrobial defense of epithelial cells.

TLRs located on the epithelial cell surface play a critical role in the very first line of defense against harmful microbes. The bacterial ligands used in this study, namely LTA, LPS, and flagellin, are recognized by TLR-2, TLR-4--MD-2 complex, and TLR-5 respectively. It is important to note that (a) activation of LPS/TLR-4 signaling requires a coreceptor MD-2 ([@bib57]), (b) epithelial cells, including those from the cornea, conjunctiva, gut, and lung, do not constitutively express this TLR-4 coreceptor and are hyporesponsive to LPS, and (c) IFN-γ has been shown to induce cell surface expression of MD-2 in these cells and confer LPS responsiveness as indicated by NF-κB activation and production of proinflammatory cytokines ([@bib1]; [@bib75]; [@bib23]; [@bib77]; [@bib93]; [@bib83]; [@bib67]). In our study, we showed that K6a network reorganization and up-regulation of cytosolic K6a and KAMPs do not occur in corneal epithelial cells that are not primed with IFN-γ, supporting the notion that the K6a-mediated antimicrobial response to LPS is TLR driven. Nevertheless, we did not exclude the possibility that other cell surface receptors, notably the scavenger receptors (SRs) and EGFR, are involved. The SR family recognizes microbial ligands, and several members have been shown to cooperate with TLRs to activate immune responses ([@bib5]). For instance, defective expression of CD36 (a class B SR) in bronchial epithelial cells weakens TLR-2 response to LTA ([@bib45]). The interplay of TLRs with EGFR has also been well established ([@bib71]; [@bib6]; [@bib7]). In the case of flagellin stimulation, EGFR can be activated without TLR-5 and NF-κB activation, potentially through an unidentified cell surface receptor, to produce AMPs LL-37 and hBD-2 and promote wound healing ([@bib15]). It is unlikely that purified flagellin used in this study was recognized by intracellular receptors such as NOD-like receptors (NLRs) because live bacteria or specialized vehicles, such as pore-forming toxins ([@bib51]) and lipid-based/liposome formulations ([@bib12]; [@bib49]), are required to deliver flagellin to the cytosol.

Accumulating evidence reveals that keratins regulate diverse cellular functions, including gene and protein expression ([@bib27]; [@bib20]), subcellular targeting of protein and organelles ([@bib59]), and cell growth, survival, and differentiation ([@bib35]; [@bib13]; [@bib59]; [@bib21]). PTMs are crucial to the functions of keratins ([@bib70]), and our data reveal new functional significance of keratin phosphorylation in innate immunity ([@bib16]), which may provide exciting insights into the association of K8/18 hyperphosphorylation and network remodeling with virus infection in hepatocytes, pancreatic acinar cells, and intestinal epithelial cells ([@bib42]; [@bib80], [@bib81]). Similar to K8, K17, and K18 phosphorylation ([@bib41]; [@bib33]; [@bib27]), K6a phosphorylation might enhance its interaction with the cytoplasmic adapter and scaffolding 14-3-3 proteins. These interactions might also limit cytosolic K6a from recycling back to the insoluble filamentous pool and thus promote its association with and ubiquitination by its E3 ligase for proteasomal processing to KAMPs. Consistent with this possibility, a motif scan of the K6a sequence indicates that S22 is a potential phosphobinding site for 14-3-3 ([@bib55]). In addition, phosphorylation of K6a might enhance its interaction with ubiquitin ligases and therefore downstream processing to KAMPs. Indeed, CRLs often prefer or even require substrate phosphorylation for binding ([@bib58]; [@bib54]; [@bib8]; [@bib40]; [@bib72]). Overall, K6a phosphorylation at distinct serine residues likely stimulates several mechanisms that contribute to KAMP production.

Intriguingly, although the flagellin-induced S19 and S22 double phosphorylation on K6a is more evident than the LPS-induced S37 phosphorylation and the LTA-induced S60 phosphorylation, all three bacterial ligands we tested were effective at triggering both solubilization and processing of K6a to increase production of KAMPs. It is possible that other PTMs, especially the labile ones such as *O*-linked glycosylation, were not detected in this study. Phosphorylation, sumoylation, acetylation, and glycosylation alone or in combination can modulate keratin solubility ([@bib73]). Indeed, we observed mono- and dimethylation of K6a arginine 16 after bacterial ligand stimulation (unpublished data). Further experiments are underway to determine whether arginine methylation also regulates K6a solubility as well as its role together with serine phosphorylation.

Mammalian cells use at least two pathways to generate bioactive AMPs, including the classical pathway of proteolytic processing of precursor peptides such as defensins and cathelicidins ([@bib39]; [@bib14]) and autophagic sequestration of cytosolic proteins such as ubiquitin and ribosomal protein rpS30 precursor Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) associated ubiquitously (FAU) followed by lysosomal degradation producing small fragments (cryptides) that have antimicrobial properties ([@bib61]; [@bib60]). Macrophages use the latter pathway against mycobacteria ([@bib61]; [@bib60]). In this study, we uncovered an unexpected role of UPS in human corneal epithelial cells as a third pathway to generating AMPs. By inhibiting proteasome activity, we demonstrated an essential role for the proteasome in generating KAMPs and regulating the antimicrobial activity of these epithelial cells and the ocular defense against bacterial colonization. Interestingly, the extent of the increase in KAMPs (product) was greater than that of cytosolic K6a (substrate) under LPS ([Fig. 2 B](#fig2){ref-type="fig"}), but not flagellin or LTA stimulation ([Fig. 2, A and C](#fig2){ref-type="fig"}), suggesting that a pathway or pathways in addition to the UPS may be involved in generating KAMPs. Although suppression of proteasome activity can also trigger activation of autophagy as a compensatory effect ([@bib79]; [@bib90]), our finding that epoxomicin significantly inhibits KAMP production ([Fig. 5, B and E](#fig5){ref-type="fig"}) demonstrates that the UPS plays a more dominant role than the potential autophagy pathway in bacterial ligand--induced KAMP production. Future studies will identify which E3 ligase ubiquitinates and targets K6a for proteasomal processing and assess the contribution of autophagy to KAMP production. Also, as KAMPs are an example of cryptides generated by the UPS, it would be of great interest to investigate whether more cryptides are generated by this system to enrich the arsenal of mucosal tissues for rapid antimicrobial protection.

In conclusion, our work identifies a novel cellular defense strategy involving finely regulated keratin cytoskeleton remodeling responses to extracellular bacterial ligands and the subsequent ubiquitin--proteasomal processing that produces KAMPs. As K6a gene expression is increased by IL-1, TNF-α, EGF, and TGF-α ([@bib4]; [@bib24]; [@bib29]) and proteasome activity is increased by IFN-γ and type I IFN ([@bib46]), we believe that cytosolic K6a level and KAMP production may be further enhanced during infection and wound healing. Therapeutic stimulation of K6a expression and phosphorylation status as well as proteasome activity may prove to be beneficial strategies for strengthening the natural immune system to prevent and fight infections.

Materials and methods {#s09}
=====================

Cell culture and treatments {#s10}
---------------------------

hTCEpi cells were maintained at 37°C and 5% CO~2~ with standard keratinocyte growth medium 2 (KGM-2) containing 0.15 mM CaCl~2~ (low Ca--KGM-2; Lonza; [@bib63]). Except for confocal microscopy and plasmid nucleofection, all experiments were performed in hTCEpi cells grown as multilayered cultures (organotypic culture) by seeding onto 3-µm polyester transwell membrane supports inserted into a six-well plate (Costar; [@bib3]). In brief, cells were maintained in low Ca--KGM-2 until confluence and then differentiated in KGM-2 containing 1.15 mM CaCl~2~ (high Ca--KGM-2) for 4 d, with media present both in the inserts and six-well compartments. Cells were then airlifted to become multilayered by exposing to high Ca--KGM-2 present only in the lower six-well compartment for 7 d and in the absence of antibiotics for the last 2 d. Cells were treated with the following reagents for various durations and dosages as indicated in figure legends, which included recombinant human IFN-γ (285-IF-100/CF; R&D Systems), purified flagellin (tlrl-pafla; from *P. aeruginosa*; InvivoGen), LTA (L2515; from *Staphylococcus aureus*; Sigma-Aldrich), LPS (L8643; from *P. aeruginosa*; Sigma-Aldrich), calyculin A (sc-24000; Santa Cruz Biotechnology, Inc.), epoxomicin (324800; EMD Millipore), and MLN4924 (505477; EMD Millipore). For confocal microscopy, human telomerase--immortalized mammary epithelial cells (hTERT-HME1 cells; Takara Bio Inc.; a gift from G. Stark, Cleveland Clinic, Cleveland, OH) and HPV-16 E6/7--immortalized human ectocervical epithelial cells (CRL-2614; ATCC) were also used. The two cell lines were maintained in Medium 171 with mammary epithelial growth supplement (Thermo Fisher Scientific) and keratinocyte--serum-free media with 0.1 ng/ml human recombinant EGF, 0.05 mg/ml bovine pituitary extract, and additional calcium chloride 44.1 mg/liter (final concentration 0.4 mM; Thermo Fisher Scientific), respectively.

Antibodies {#s11}
----------

Rabbit polyclonal antiserums were raised against 10-mer KAMP (GGLSSVGGGS; Pacific Immunology) or 19-mer KAMP (RAIGGGLSSVGGGSSTIKY; New England Peptide), which correspond with amino acid residues 537--546 and 533--551, respectively, of the carboxyl terminal region of K6a. Both antibodies recognize full-length K6a and KAMPs. Other antibodies used were all mouse monoclonal, which included antiphosphoserine antibody (clone 4A4; EMD Millipore), antimonoubiquitination/antipolyubiquitin antibody (clone FK2; Enzo Life Sciences), anti-HA antibody (clone 16B12; BioLegend), and antiactin antibody (clone 8D10D10; Cell Signaling Technology).

Immunocytochemistry and confocal microscopy {#s12}
-------------------------------------------

hTCEpi cells at 90% confluence on Millicell EZ slides (EMD Millipore) were fixed with 4% paraformaldehyde in PBS for 15 min and permeabilized with 0.1% Triton X-100 in PBS supplemented with 5% BSA (wt/vol) for 15 min. Cells were blocked with 5% BSA for 1 h to reduce nonspecific binding of antibodies. K6a was stained with Alexa Fluor 488--labeled anti--19-mer KAMP antibody in 5% BSA at 4°C overnight. Nuclei were stained by propidium iodide or DAPI in mounting medium. Confocal images were captured with a TCS SP8 microscope using a 40× oil immersion objective (1.30 NA) and a zoom factor 2 or 3 (Leica Microsystems).

Western blot detection of K6a and KAMPs {#s13}
---------------------------------------

hTCEpi cells were stimulated with bacterial ligands for 16 h. Bacterial ligands used were 0.5 µg/ml flagellin (FliC), 1 µg/ml LTA, or 1 µg/ml LPS. Before LPS stimulation, cells were pretreated with 250 ng/ml of IFN-γ for 2 h. After stimulation, cells were trypsinated by 1× trypLE (Thermo Fisher Scientific), washed with PBS, and lysed with NP-40 lysis buffer (1% \[vol/vol\] NP-40 in 20 mM Hepes, pH 7.4, 120 mM NaCl, 1 mM EDTA, and 1× protease and phosphatase inhibitor cocktail) for 15 min on ice. Soluble fractions containing cytosolic K6a and KAMPs were collected by centrifugation at 15,000 *g* for 10 min at 4°C. Insoluble pellets containing filamentous K6a were dissolved in 2% SDS buffer. Protein concentrations were determined by BCA assay (Thermo Fisher Scientific). Samples were resolved in 12% Bis-Tris protein gels (NuPAGE) and immunoblotted with anti--19-mer KAMPs antiserum to detect cytosolic and filamentous K6a, or they were resolved in 16% tricine gels (Thermo Fisher Scientific) and immunoblotted for KAMPs. Actin served as the loading control. Gels were transferred to 0.1-µm nitrocellulose membrane (GE Healthcare) using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories). VisiGlo Select HRP chemiluminescent substrate (Amresco) and Pierce ECL Western blotting substrate (Thermo Fisher Scientific) were used to detect KAMPs and K6a/actin respectively.

Real-time quantitative RT-PCR {#s14}
-----------------------------

hTCEpi cells were stimulated with bacterial ligands for 3 or 6 h as described for Western blot detection of KAMPs and K6a. After treatment, cells were lysed by TRI reagent (Ambion), and total RNA was extracted with Direct-Zol RNA miniprep kit (Zymo Research). Purified RNA was reverse-transcribed with oligo-dT reverse primers and synthesized into cDNA with a Maxima H minus first-strand cDNA synthesis kit (Thermo Fisher Scientific). Real-time PCR was performed with a Luminaris color probe quantitative PCR master mix (Thermo Fisher Scientific) on a LightCycler 480 system (Roche) with predesigned TaqMan probe-primer sets (Integrated DNA Technologies) for K6a (Hs.PT.58.26132549.g), β-actin (Hs.PT.39a.22214847), and GAPDH (Hs.PT.39a.22214836) mRNAs. Thermal cycling reactions were consisted of 10 min of denaturation at 95°C followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. Standard curves of housekeeping genes and K6a were generated to validate their equal efficiencies of amplification. Gene expression was normalized to β-actin and expressed as 2^-ΔΔCT^ relative to mock-treated cells.

Liquid chromatography--tandem mass spectrometry (LC-MS) analysis of phospho- and ubiquitinated peptides {#s15}
-------------------------------------------------------------------------------------------------------

For mass spectrometry analysis of K6a PTMs, hTCEpi cells were stimulated with bacterial ligands and then lysed with NP-40 lysis buffer. Cytosolic extract (500 µg total protein) was precleared and then incubated overnight with 20 µl of anti--10-mer KAMP-conjugated agarose beads. Washed beads were eluted in 20 µl of Laemmli's buffer at 95°C for 10 min, resolved in 12% Bis-Tris protein gels (NuPAGE), and stained by Coomassie Blue dye. K6a-containing gel bands (∼60 kD) were excised from the gel, digested with trypsin or chymotrypsin, and analyzed by a capillary column LC-MS system. The LC-MS system consisted of an Acclaim PepMap 100 Å--pore-size C18 reversed phase capillary chromatography column (Thermo Fisher Scientific) that was programmed to run at standard liquid chromatography gradient from 2--70% acetonitrile in 110 min and an LTQ-Orbitrap Elite hybrid mass spectrometer (Thermo Fisher Scientific) with the microelectrospray ion source operated at 2.5 kV. Collision-induced dissociation spectra were collected and searched against the K6a sequence using the Sequest algorithm ([@bib10]) for K6a PTMs. The parameters used in this search included a peptide mass accuracy of 10 ppm, fragment ion mass accuracy of 0.6 D, carbamidomethylated cysteines as a constant modification, and oxidized methionine, lysine acetylation, and phosphorylation at S, T, and Y as a dynamic modification. The results were filtered based on Mascot ion scores and Sequest XCorr scores. All positively identified phosphopeptides were manually validated. The degree of phosphorylation of each peptide was determined by plotting chromatograms for the unmodified and phosphorylated forms and calculating the peak area ratios (phosphorylated/unmodified form; [@bib87]; [@bib84]).

Immunoprecipitation {#s16}
-------------------

For phospho-K6a and Ub-K6a analyses, hTCEpi cells were lysed by radioimmunoprecipitation assay (RIPA) buffer with 1× Halt protease and phosphatase inhibitor cocktail (Cell Signaling Technology) or in addition 10 mM *N*-ethylmaleimide (Sigma-Aldrich) to inhibit the action of deubiquitinases. Lysates were collected and precleared by centrifugation at 14,000 rpm for 20 min at 4°C. Precleared lysate (500 µg total protein) was mixed with 30 µl of anti--19-mer KAMP antiserum or preimmune serum for 2 h at 4°C followed by incubation with protein A/G plus agarose beads (Santa Cruz Biotechnology, Inc.) overnight. After six washes in RIPA buffer, immunoprecipitated proteins were eluted from the beads by incubating in 50 µl of Laemmli's buffer at 95°C for 10 min. Eluted samples were resolved in Mini-Protean TGX 7.5% precast gel (Bio-Rad Laboratories) and immunoblotted with anti--19-mer KAMP antiserum, antiphosphoserine antibody, and antiubiquitin antibody for total K6a, phospho-K6a, and Ub-K6a, respectively. HRP-conjugated goat anti--mouse (Bio-Rad Laboratories) and conformation-specific mouse anti--rabbit (clone L27A9; Cell Signaling Technology) IgG (H+L) secondary antibodies were used accordingly. Dephosphorylation of the transferred K6a was performed on the immunoblot membrane using calf alkaline phosphatase (CIP; Cell Signaling Technology) in a buffer containing 100 mM Tris-HCl, pH 7.9, 50 mM NaCl, 10 mM MgCl~2~, and 1 mM dithiothreitol for 1 h at 37°C.

Plasmids and site-directed mutagenesis {#s17}
--------------------------------------

To construct the mammalian expression vector encoding HA~3~-K6a, we used pCMV3-His-K6a (Sino Biological Inc.) as the PCR template, 5′-ATATGAATTCGCCACCATGGCCTACCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGCAGGATATCCATATGACGTTCCAGATTACGCTGGTGCCAGCACATCCACCACCATC-3′ as the EcoRI site--containing forward primer, and 5′-ATATGCGGCCGCTTAGTGCTTGTAGCTCTTCCTGCTGGAG-3′ as the NotI site--containing reverse primer. Cloning of the K6a cDNAs into EcoRI- and NotI-digested pEGFP-N1 (Takara Bio Inc.) resulted in the removal of the EGFP sequence. Single or tandem site-directed mutagenesis of HA~3~-K6a to generate single or multiple serine-to-alanine mutations was performed using the QuikChange II XL site-directed mutagenesis kit (Promega). Primer sequences are shown in [Table 1](#tbl1){ref-type="table"}.

###### Primer sequences for site-directed mutagenesis of HA~3~-K6a

  Site            Strand      Mutagenic primer sequence (5′--3′)
  --------------- ----------- --------------------------------------
  S19A            sense       `GCCGCCGGGGTTTCGCTGCCAACTCAGCC`
  S19A            antisense   `GGCTGAGTTGGCAGCGAAACCCCGGCGGC`
  S22A            sense       `GTTTCAGTGCCAACGCAGCCAGGCTCCCT`
  S22A            antisense   `AGGGAGCCTGGCTGCGTTGGCACTGAAAC`
  S19A and S22A   sense       `CGCCGGGGTTTCGCTGCCAACGCAGCCAGGCTCC`
  S19A and S22A   antisense   `GGAGCCTGGCTGCGTTGGCAGCGAAACCCCGGCG`
  S37A            sense       `CTTCAGCAGCGTCGCCGTGTCCCGCTC`
  S37A            antisense   `GAGCGGGACACGGCGACGCTGCTGAAG`
  S60A            sense       `CCAGGCCATACAGAGCGCGGCTGCCAAAGC`
  S60A            antisense   `GCTTTGGCAGCCGCGCTCTGTATGGCCTGG`

Plasmid nucleofection {#s18}
---------------------

Mammalian expression vectors encoding HA~3~-tagged WT K6a or serine-to-alanine mutants were introduced to hTCEpi cells using the AMAXA Basic Nucleofector kit for Primary Mammalian Epithelial Cells (Lonza). Cells at a concentration of 2 × 10^6^ cells/100 µl of nucleofector solution containing 2 µg of plasmid were loaded into the transfection cuvette and electroporated using program U-20. Nucleofected cells were recovered in 600 µl of low Ca--KGM-2 in 2-ml Eppendorf tubes and were placed at 37°C for 30 min. Cells were plated at the desired density into 24-well plates and maintained in low Ca--KGM-2 at 37°C and 5% CO~2~ for 72 h before harvest.

Cell viability and proteasome activity assays {#s19}
---------------------------------------------

hTCEpi cells were treated with 0, 50, 100, or 200 nM of epoxomicin in high Ca--KGM-2 for 2 h, cotreated with the same amounts of epoxomicin and LTA at 1 µg/ml for 16 h, and washed by PBS. Cells were assessed for viability and proteasome activity using an MTT growth assay (EMD Millipore) and a proteasome-Glo trypsin-like cell-based assay (Promega), respectively, according to the manufacturers' instructions. A Wallac microplate reader (PerkinElmer) was used to measure absorbance or bioluminescence.

In vitro antimicrobial assay {#s20}
----------------------------

hTCEpi cells were trypsinated, washed, and lysed with sterile saline by three cycles of freeze and thaw. Preparation of \<10-kD cytosolic lysate fractions and antimicrobial assays against *P. aeruginosa* (cytotoxic strain 6206) were performed as described previously ([@bib78]). In brief, lysates (1 mg/ml) normalized by BCA assays were fractionated at 4°C using a series of water-prerinsed Vivaspin protein concentrators with membrane cutoff at 100, 30, or 10 kD (GE Healthcare). All filtrates, including the \<10-kD fractions, were normalized to the initial volume with saline. The inoculum was consisted of a *P. aeruginosa* culture at 10^8^ colony-forming units (CFUs)/ml (OD~650~ reading at 0.1) in keratinocyte basal medium 2 (KBM-2; Lonza) diluted 100-fold in \<10-kD lysate fractions. The mixtures were incubated for 3 h at 37°C followed by 10-fold serial dilutions by PBS and plated onto tryptic soy agar plates. After incubation overnight, the number of colonies in the agar plates was counted and adjusted for the dilution factor to derive viable bacterial counts (CFU/ml).

Murine models of bacterial clearance from the ocular surface {#s21}
------------------------------------------------------------

All procedures were conducted in compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic. Bacterial culture supernatant was prepared by growing *P. aeruginosa* strain PAO1 overnight with aeration in tryptic soy broth at 37°C followed by centrifugation at 16,000 *g* for 30 min and sterilization with a 0.22-µm filter. Epoxomicin (5 µl of 16 µM per eye) or vehicle control was injected subconjunctivally and applied topically (once each) to 8--10-wk-old sex-matched C57BL/6J mice (The Jackson Lab). After 2 h, the eyes were inoculated three times within an hour with bacterial culture supernatant (5 µl per eye) to up-regulate expression of defense factors ([@bib44]; [@bib3]; [@bib74]). The procedure of topical administration of epoxomicin and bacterial culture supernatant was repeated once after 24 h. Slit-lamp examination of mouse eyes was used to confirm that the physical barrier (i.e., tight junctions) of the corneas remained intact after epoxomicin treatment, as indicated by the absence of corneal staining with fluorescein. To assess the susceptibility of corneas to bacterial adhesion in the absence of other confounding host factors, mice were sacrificed by lethal injection of anesthetic cocktail (25 mg/ml ketamine and 0.2 mg/ml dexmedetomidine), and whole eyes were enucleated and rinsed with PBS to exclude tear fluid followed by incubation with 200 µl carbenicillin-resistant GFP-expressing *P. aeruginosa* strain PAO1 (PAO1-GFP; 10^11^ CFU/ml) for 3 h at 35°C as previously described ([@bib2]; [@bib78]). After extensive rinsing with PBS, corneas were excised and homogenized in PBS to collect viable bacteria adhered to the cornea followed by quantification by plating on tryptic soy agar supplemented with 300 µg/ml carbenicillin. To assess bacterial clearance from the ocular surface in vivo as previously described ([@bib52]; [@bib17]), mice were inoculated with 10*^7^* CFU (in 5 µl) of PAO1-GFP after i.p. injection of anesthetic cocktail. At 3 h after inoculation, 4 µl of PBS was added to the ocular surface and then collected immediately using a 10-µl-volume glass Drummond capillary tube placed at the lateral canthus. The number of viable bacteria within the ocular surface washes was quantified by plating on tryptic soy agar.

Statistics {#s22}
----------

All experiments except the animal experiments were analyzed by the unpaired two-tailed Student's *t* test to determine p-values. The nonparametric Mann-Whitney *U* test was used to analyze animal experiments. All experiments were performed at least three times. P \< 0.05 was considered significant.

Online supplemental material {#s23}
----------------------------

Fig. S1 contains confocal images of K6a filament network reorganization in human mammary epithelial cells and ectocervical epithelial cells in response to bacterial ligands. Fig. S2 contains confocal images of K6a filament network in human corneal epithelial cells showing that priming the cells with IFN-γ is required for LPS-induced network reorganization. Figs. S3 and S4 contain supporting data for [Fig. 3 A](#fig3){ref-type="fig"} showing the tandem mass spectrometry spectra for K6a peptides with a single phosphorylation site at serines 22, 37, or 60 or double phosphorylation sites at serines 19 and 22. Fig. S5 contains supporting data for [Fig. 5 C](#fig5){ref-type="fig"} showing the tandem mass spectrometry spectra for K6a peptides ubiquitinated at lysines 180, 194, and 204.
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